Axsome Therapeutics, Inc.
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as wā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$235.32
Price+5.04%
$11.29
1Y
Price
Market Cap
$12.110b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-31.9%
EBITDA Margin-33.8%
Net Profit Margin-10.9%
Free Cash Flow Margin-31.9%
EBITDA Margin-33.8%
Net Profit Margin-10.9%
Free Cash Flow MarginRevenue
$708.236m
+10.9%
1y CAGR+39.7%
3y CAGR+140.0%
5y CAGREarnings
-$188.303m
-2.8%
1y CAGR+4.5%
3y CAGR-3.6%
5y CAGREPS
-$3.73
-1.4%
1y CAGR+7.9%
3y CAGR+2.2%
5y CAGRBook Value
$54.587m
$713.607m
Assets$659.020m
Liabilities$216.707m
DebtDebt to Assets
30.4%
-1.2x
Debt to EBITDAFree Cash Flow
-$70.993m
+24.4%
1y CAGR+21.0%
3y CAGR+9.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company